BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Theofilis P, Vordoni A, Kalaitzidis RG. Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations. World J Gastroenterol 2022; 28(39): 5691-5706 [PMID: 36338895 DOI: 10.3748/wjg.v28.i39.5691]
URL: https://www.wjgnet.com/1007-9327/full/v28/i39/5691.htm
Number Citing Articles
Kristine Griffett, Thomas P. Burris. Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseasesFrontiers in Medicine 2023; 10 doi: 10.3389/fmed.2023.1102469
Panagiotis Theofilis, Aikaterini Vordoni, Vasilis Tsimihodimos, Rigas G. Kalaitzidis. Metabolic Dysfunction-Associated Fatty Liver Disease in Newly Diagnosed, Treatment-Naive Hypertensive Patients and Its Association with Cardiorenal Risk MarkersHigh Blood Pressure & Cardiovascular Prevention 2023; 30(1): 63 doi: 10.1007/s40292-023-00558-5
Maria Sole Valentino, Pierluigi Marzuillo, Claudia Esposito, Mario Bartiromo, Michele Nardolillo, Annalisa Valentina Villani, Alessandro Maresca, Giuseppe Furcolo, Stefano Guarino, Emanuele Miraglia del Giudice, Anna Di Sessa. The Impact of COVID-19 Pandemic Lockdown on the Relationship between Pediatric MAFLD and Renal FunctionJournal of Clinical Medicine 2023; 12(5): 2037 doi: 10.3390/jcm12052037
Panagiotis Theofilis, Aikaterini Vordoni, Rigas G. Kalaitzidis. Trimethylamine N-Oxide Levels in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-AnalysisMetabolites 2022; 12(12): 1243 doi: 10.3390/metabo12121243